The Medicare GLP-1 Bridge Program: What It Actually Covers in 2026

For years, Medicare Part D didn't cover GLP-1s prescribed specifically for weight loss, full stop — a policy gap we note in do GLP-1 savings cards actually lower the price?, since manufacturer savings cards also exclude government insurance. That changed in 2026. Here's what the new Medicare GLP-1 Bridge program actually covers, sourced to CMS's own program details rather than to headlines.

What the Bridge program is

The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027 (extended from an original end date of December 31, 2026), providing eligible Medicare Part D beneficiaries access to specific GLP-1 medications through a negotiated arrangement¹. It covers "all formulations of both Foundayo and Wegovy and the KwikPen formulation of Zepbound"¹ — Foundayo being the brand name for orforglipron, Eli Lilly's oral GLP-1. Notably, Ozempic and Mounjaro are not listed among the Bridge-covered drugs, and Zepbound coverage is specifically limited to the KwikPen formulation, not every available format.

What it actually costs

Eligible beneficiaries pay a flat $50 per month copayment at the pharmacy for a covered drug¹. Behind that copay, manufacturers agreed to supply the medications to the program at "a net price of $245 per month supply"¹ — a steep discount off typical list prices, made possible by the volume and certainty of a federal program rather than individual negotiation. One structural catch worth knowing: the $50 copayment does not count toward your Part D deductible or your annual out-of-pocket maximum¹ — meaning it's a flat add-on cost, not a credit against other drug spending you're tracking toward catastrophic coverage. If you're enrolled in the Low-Income Subsidy (LIS) program, the standard LIS cost-sharing subsidies don't apply to the Bridge's own copay structure¹ — the $50 rate is the rate, regardless of your LIS status.

Who actually qualifies

Eligibility isn't automatic just because you're on Medicare — beneficiaries must meet one of three clinical categories that combine specific BMI thresholds with comorbidities¹, and your provider must submit prior authorization attesting that you're "being prescribed the drug to reduce excess body weight and ongoing maintenance of weight reduction"¹. That prior-authorization step means a program or prescriber who simply hands you a prescription without documenting your BMI and comorbidity status against the actual eligibility categories isn't doing the paperwork the Bridge requires — ask directly whether your prescriber's practice has experience submitting Bridge prior authorizations, not just whether they'll write the prescription.

The related Medicaid program: BALANCE

A separate, broader initiative — the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model — targets Medicaid rather than Medicare Part D, running May 1, 2026 through December 31, 2031². BALANCE's drug list is wider than the Bridge's: "all formulations of Foundayo, Mounjaro, Ozempic, Rybelsus, and Wegovy, and the KwikPen formulation of Zepbound"². The Medicare Part D component of BALANCE itself was indefinitely delayed, with the Bridge program serving as the interim Medicare coverage option in its place² — worth knowing if you see "BALANCE" referenced somewhere and assume it means the same coverage as the Bridge; for Medicare beneficiaries specifically, right now, the Bridge is the operative program.

What this doesn't change

The Bridge is a specific, time-limited program with specific covered drugs and specific eligibility rules — it is not a general statement that "Medicare covers GLP-1s now." If your prescribed drug is Ozempic or Mounjaro rather than a Bridge-covered formulation, or if you don't meet the clinical eligibility categories, none of this applies to you, and the older gap — no standard Part D coverage for weight-loss GLP-1s outside this program — still stands. Compounded and cash-pay options remain the realistic path for a lot of Medicare beneficiaries outside the Bridge's specific drug list; see the cheapest legit way to start GLP-1 for that comparison.

Where this fits your decision

If you're on Medicare and considering a GLP-1, ask your prescriber directly whether you fit one of the Bridge's clinical eligibility categories and whether their practice handles the prior-authorization submission — that single conversation determines whether you're looking at a $50 monthly copay or full cash-pay pricing. Compare cash-pay alternatives on our semaglutide and tirzepatide boards if the Bridge doesn't apply to your situation, and see how insurance and coverage factors weigh into our Value Score methodology.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.